Our liver transplant program is one of the world's oldest

Current liver research

Liver Clinical Trials	Sponsor	Lead
Completed - A phase II, open-label, multi-center study to assess the pharmacokinetics, long-term safety and tolerability of Tacrolimus in stable liver transplant patients converted from a Prograf based immunosuppression regimen to a modified release (MR) Tacrolimus based immunosuppression regimen	Fujisawa Healthcare	Lake
Safety & Efficacy of Adefovir Dipivoxil for the Treatment of Liver Disease due to Lamivudine-Resistent Hepatitis B Virus (HBV) in Liver Transplant Patients	Gilead	Lake
Multi-center, randomized, double-blind, placebo-controlled study of the safety and efficacy of an investigational drug on progression of renal disease and significant clinical events in patients with Fabry disease	Genzyme	Whitley
A prospective, randomized, open label, twenty-six week study of the efficacy and safety of converting kidney and liver transplant recipients with a tacrolimus-associated abnormal glucose metabolism to Neoral with C2 monitoring	Novartis Pharmaceuticals	Lake
A Randomized, Controlled, Multicenter Study of Thymoglobulin Induction Therapy with a Calcineurin-Sparing Regimen in Liver Transplant Patients	Wyeth-Ayerst	Lake
The aim of this study is to evaluate the safety and efficacy of solid organ transplantation in people with HIV disease by conducting a prospective, multi-center cohort study of HIV-positive (+) patients who undergo kidney or liver transplantation. Our long-range goals are: 1) to provide patients and clinicians with information regarding the risks of transplantation, 2) to provide clinicians with information necessary to manage immunosuppressive and antiretroviral (ARV) medications together, and (3) to understand underlying mechanisms that explain patient outcomes so that clinical management may be adjusted to maximize outcomes. Our primary aims are: 1) To evaluate the impact of immunosuppression (IS) in HIV+ liver and kidney transplant recipients on patient survival and 2) To evaluate the impact of HIV infection and HAART on graft survival. The secondary aims are 1) to explore the impact of post-transplant immunosuppression on changes in CD4+ T cell counts and HIV-1 RNA levels; 2) To explore the impact of post-transplant immunosuppression on the host-response to viral co-pathogens, including hepatitis B and C, the human herpesviruses (CMV, EBV, HHV-6, HHV-8) and HPV; 3) To explore the impact of HIV infection on the alloimmune response and rejection rates; and 4) To explore the pharmacokinetic interactions between immunosuppressive agents and the hepatically metabolized antiretroviral agents.	National Institutes of Health	Humar

More trials are in preparation or ongoing. Contact the Transplant Center for more information.